Hepatic insulin resistance is associated with hepatic steatosis and is thought to play an important role in the pathogenesis of steatohepatitis. Using a murine model of steatohepatitis (mice fed a diet deficient in methionine and choline-MCD diet), we tested the effects of the insulin-sensitising, PPARc agonist drug pioglitazone (PGZ) on systemic and intrahepatic insulin sensitivity and on liver pathology. Compared to controls, mice fed the MCD diet develop a significant steatohepatitis, have enhanced glucose tolerance and enhanced systemic response to insulin. PGZ did not affect the systemic insulin sensitivity in control or MCD-fed mice as assessed in vivo by intraperitoneal glucose or insulin dynamic tests. However, PGZ prevented hepatic fat accumulation and steatohepatitis induced by the MCD diet. This effect was associated with an increased mass of adipose tissue and increased expression and release of adiponectin, while hepatic acyl co-enzyme A oxidase and acyl-coenzyme A carboxylase, regulating hepatic b-oxidation of fatty acid, remained unchanged. Steatohepatitis in MCD-diet-fed mice was associated with intrahepatic insulin resistance as shown by a reduced phosphorylation of hepatic insulin receptor, and Akt in response to an insulin stimulus. PGZ to MCD-fed mice restored the activation of the insulin receptor and of the Akt pathway in response to insulin. In conclusion, PGZ alleviates steatosis and steatohepatitis induced by the MCD diet, an effect associated with correction of intrahepatic insulin resistance. Laboratory Investigation ( The thiazolidinediones (TZDs) are a class of antidiabetic drugs which allow the normalisation of blood glucose without a concomitant risk of hypoglycaemia.
The thiazolidinediones (TZDs) are a class of antidiabetic drugs which allow the normalisation of blood glucose without a concomitant risk of hypoglycaemia. 1, 2 Their potent insulin-sensitising effect is mediated via ligand activation of transcription factor peroxisome proliferator-activated receptor gamma (PPARg), which controls transcription of genes involved in lipid metabolism, glucose transport and metabolism, energy balance and production of adipokines such as adiponectin and TNF. [2] [3] [4] [5] Despite the wide usage of these drugs, the respective roles of various PPARg-expressing target cell types and the precise molecular mechanisms underlying TZD action are not completely understood. 2, 6 PPARg is abundantly expressed in adipocytes and is important for adipocyte differentiation. 7 Adipocytes are believed to be the primary site of action of TZDs. 8, 9 However, in animal models of lipoatrophy, TZDs still have beneficial insulin-sensitising effects in the near absence of adipose tissue, 10 suggesting that PPARg agonists may act directly on non-adipose tissues. 11 Targeted deletion of PPARg in muscle leads to insulin resistance. 12, 13 Mice without liver PPARg also develop insulin resistance, but respond to TZDs by lowering serum glucose and insulin levels and improved glucose clearance. 10 It is, therefore, unclear whether PPARg in liver and muscle are direct target for TZDs action or whether the antidiabetic effects in liver and muscle are secondary to TZD action in adipocytes through induction of an adipocyte-derived hormonal factor. Beside, PPARg is also expressed in other cell types such as macrophages, vascular endothelial cells or hepatic stellate cells suggesting a more pleiotropic role in multiple fundamental pathways as diverse as the control of inflammatory reaction (which can also in turn influence insulin sensitivity), atherosclerosis or hepatic fibrosis.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common cause of liver disease worldwide. 18 The two basic histological lesions in subjects with NAFLD are steatosis and steatohepatitis (termed non-alcoholic steatohepatitis or NASH), the latter being characterised by the presence of hepatocellular damage, inflammation and progressive fibrosis. 19 The pathogenesis of NASH remains ill-defined. The prominent association with insulin resistance suggests that this condition may contribute to the pathogenesis of NAFLD by promoting the development of steatosis and the subsequent cell injury and inflammation leading to NASH. 20 Insulin resistance increases peripheral lipolysis and delivery of free fatty acids to the liver. It is associated with hyperinsulinemia, which stimulates intrahepatic lipogenesis, and thereby induces intrahepatic lipid storage (steatosis). The liver is a target organ for insulin. Binding of insulin to its receptor (IR) induces its autophosphorylation, which, via phosphorylation of insulin receptor substrate (IRS) proteins, activates two main signalling pathways. The PI3K/Akt pathway is responsible for most of the metabolic actions of insulin governing hepatic storage and release of glucose according to the metabolic needs, and the ras-mitogen-activated protein kinase (MAPK) pathways controls cell growth and proliferation. Resistance in the metabolic pathway results in persistence of hepatic glucose output in the face of hyperinsulinemia, which participates in the maintenance of hyperglycemia and resulting stimulation of insulin secretion, and to the aggravation of insulin resistance. 21 Hepatic insulin resistance is associated with the development of hepatic steatosis, but the link between the two remains unclear. 22 Some have postulated that the combination of insulin resistance, hyperglycemia and increased concentrations in circulating fatty acids promote hepatic lipid synthesis and impair hepatic b-oxidation leading to hepatic steatosis. 22, 23 Others have proposed that hepatic fat accumulation and hepatic insulin resistance can occur without the development of peripheral (or systemic) insulin resistance. [24] [25] [26] In addition, while impaired regulation of hepatic glucose output is documented in patients with NASH, 23 it is still ill-defined whether and how impaired hepatic insulin signalling is implicated in the promotion and the progression of steatohepatitis.
Mice fed a lipogenic methionine and choline deficient (MCD) diet develop a steatohepatitis mimicking hepatic lesions seen in patients with NASH. [27] [28] [29] [30] [31] [32] However, contrasting with obesity and metabolic syndrome associated with human NASH, MCD-fed mice lose weight and do not have systemic (or peripheral) insulin resistance. 33 Despite this, a recent study suggests that they exhibit intrahepatic resistance to the action of insulin. 34 PPARg agonists TZDs have been shown to improve hepatic steatosis in several hepatic disease models in rodent. The aim of this study was to analyse the effect of the treatment by the TZD pioglitazone (PGZ) on liver pathology in MCD-fed mice, and to analyse the consequences of this on systemic and intrahepatic response to insulin.
Materials and methods

Animals and Experimental Protocols
Female C57BL6/J mice (8-10 weeks old) were randomly divided into four experimental groups and fed a powdered (a) lipogenic MCD diet (cat. no. 960439, ICN, Aurora, OH, USA), (b) MCD diet supplemented with PGZ at 0.01% (w/w) (gift from Takeda, Japan), (c) control diet (MCD diet supplemented with DL-methionine (3 g/kg) and choline chloride (2 g/kg); cat. no. 960441, ICN) or (d) control diet supplemented with PGZ at 0.01% (w/w). Mice (five per group) were allowed food and water ad libitum for 4 weeks. All studies were approved by the local Ethics Committee for Animal Use. At the end of the feeding experiment, mice were euthanised, blood collected and livers excised. A part of the right posterior lobe was fixed in 10% formalin. The remaining liver was snap frozen. Subcutaneous fat from the abdominal area was removed and weighted.
In a separate experiment and after completion of a 4-week feeding protocol, mice from the 4 dietary groups were either injected insulin (5 U; n ¼ 4 per treatment group) or a similar volume of PBS (n ¼ 4 per treatment group) in the portal vein, 5 min before the resection of the liver, to analyse the intrahepatic response to insulin.
Morphological Studies
Sections (4 mm thick) from formalin-fixed liver tissue were stained with haematoxylin and eosin. Hepatic inflammation was quantified as the ratio of the area of inflammatory foci (defined as groups of five or more inflammatory cells) to the total area of the section. 28 Two different sections of each liver were examined on coded slides.
Biochemical Assays
Serum alanine aminotransferase (ALT) levels were measured using automated techniques. Hepatic total lipid content was measured as described. 27 Insulin, leptin and adiponectin serum concentrations were determined using commercial mouse ELISA or radio-immunoassays (Linco Research, St Charles, MI, USA). At 1 week before harvest, mice were tested for their tolerance to glucose and their response to insulin. Glucose (1.5 g/kg body weight) was injected i.p. on 4 h fasting animals and glucose levels were monitored on tail blood 0, 15, 30, 60, 90 and 120 min after the injection. Systemic response to insulin was assessed by monitoring blood glucose levels 0, 15, 30, 45, 60 and 120 min after the injection of insulin (0.5 U/kg body weight i.p.) administered after overnight fasting.
Immunoquantitation of Proteins
Liver homogenates were prepared in a buffer containing Triton X-100 0.1%, Hepes 50 mM, NaCl 150 mM, Glycerol 10%, MgCl 2 1.5 mM, DTT 0.5 mM, PMSF 125 mM, aprotinin 50 mg/ml, leupeptin 5 mg/ml, NaF 0.5 mM, NaVO 4 50 mM and used in Western blot assays. Total and phosphorylated forms of IR, IRS1, IRS2, Akt, extracellular signal-regulated kinase (ERK) 1/2 (p42/44), Acyl co-enzyme A-carboxylase (ACC) were assayed by Western immunoblots. After separation by SDS-PAGE, proteins were transferred onto PVDF membrane (NEN Life Science Products, Boston, MA, USA). Membranes were blocked and then incubated first with anti-phospho-protein antibody (p-IR Santa Cruz; Pser307 IRS1, p-Akt, and p-ACC Cell Signalling; p-ERK, BD Transduction Laboratories) and exposed to peroxidase-conjugated anti-mouse secondary antibodies. Immunoreactive bands were visualised by enhanced chemiluminescence (Western Lightning Chemiluminescence Reagent Plus, Perkin-Elmer, Boston, MA, USA) and exposure to autoradiograph film. The membranes were then stripped and reprobed with an antibody against the corresponding total protein (BD Transduction Laboratories, Cell Signalling or Santa Cruz) and then with b-actin (Sigma, St Louis, MO, USA) or HSP90 (BD Transduction Laboratories) to serve as an internal control for protein loading.
mRNA Analyses
Total RNA was prepared from frozen liver or from frozen subcutaneous adipose tissue using TRIpure isolation reagent (Roche). Hepatic mRNA expression levels of murine type I collagen-a-1 (Col-I), transforming growth factor b1 (TGFb1), acyl-coenzyme A oxidase (ACO), cytochrome P450 2E1 (CYP2E1), CD36, aP2, PPARg-1 and phosphoenolpyruvate carboxykinase (PEPCK) were quantitated by realtime PCR. mRNA levels for CD36, aP2, PPARg-1, leptin and adiponectin were determined in adipose tissue. Primer pairs for transcripts of interest were designed using the Primer Expresst design software (Applied Biosystems). The ABI Prism 5700 PCR platform and SYBRgreen s mastermix were used for detection of the amplification product. The relative amount of mRNA was calculated by reference to a calibration curve and normalised to the level of expression of RPL19 mRNA, an invariant control.
Statistical Analyses
Results are presented as mean7standard deviation. The two-way ANOVA and Student's t-test were used to compare data from different treatment groups. When P was less than 0.05, differences were considered significant.
Results
Pioglitazone Confers Protection against Steatohepatitis Induced by the MCD Diet
Mice fed the MCD diet for 4 weeks developed prominent hepatic macrovesicular steatosis, conspicuous inflammation forming intralobular foci associated with increased hepatic lipid content and elevation of serum ALT levels ( Figure 1c , Table  1 ). No or little hepatic fibrosis developed after 4 weeks MCD feeding as assessed on Sirius redstained liver sections (not shown). However, in those mice, hepatic type I collagen-a-1, and TGFb1 mRNA were significantly upregulated compared to control animals signing early fibrogenesis (Figure 1e and f). PGZ significantly reduced the severity of hepatic steatosis and inflammation induced by the MCD diet ( Figure 1d ). It also significantly decreased intrahepatic lipid content, serum ALT levels and hepatic area occupied by inflammatory infiltrates (Table 1) compared to MCD-fed mice. In addition, PGZ treatment prevented the upregulation of hepatic collagen I and TGFb1 mRNA expression seen after MCD feeding (Figure 1e and f) .
Effect of MCD Diet and PGZ on Peripheral Response to Insulin
As previously described, mice fed the MCD diet for 4 weeks lost body weight ( Table 2) . Fasting blood glucose as well as fasting insulin levels were significantly lower in mice fed the MCD diet compared to controls, but serum leptin and adiponectin levels remained unaffected by the MCD diet ( Table 2 ). After intraperitoneal glucose challenge, blood glucose levels increased less and were at all time lower in MCD-fed mice than in controls ( Figure  2a ) such as the area under the curve (AUC) of serum glucose was significantly lower in MCD compared to control-fed mice (Figure 2b ). Intraperitoneal injection of insulin caused a more rapid and more pronounced reduction in blood glucose in MCDfed mice than in control mice (Figure 2c ). These results indicate enhanced glucose tolerance and insulin hypersensitivity in MCD-fed mice, in accordance with observations by others. 33 PGZ given together with the control or the MCD diet did not modify the body weight evolution (Table 2) . However, consistent with its adipogenic action, 2, 35 PGZ significantly increased the mass of subcutaneous abdominal fat in both controls and MCD-fed mice (Table 2) . Accordingly, PGZ treatment to both control and MCD-fed diet was associated with increased adipose expression of CD36 and adiponectin mRNA, two genes regulated by PPARg (Table 3) .
PGZ did not induce significant difference in fasting glucose, insulin or leptin levels in controls nor in MCD-fed mice, but PGZ increased serum adiponectin concentrations by a factor 2 in both dietary groups ( Table 2 ). The systemic responses to insulin load were not altered by PGZ treatment in any of the dietary groups (Figure 2c ). After glucose challenge, serum glucose levels decreased more rapidly in PGZ MCD-fed mice but not in PGZ control mice (Figure 2a and b) .
Effect of MCD Diet and PGZ on Intrahepatic Response to Insulin
To assess the intrahepatic insulin sensitivity, we evaluated phosphorylation of intermediate proteins along the insulin-receptor signalling pathway in response to insulin in the various dietary groups.
There was no significant difference in the level of expression of the insulin receptor (IR) between CTL and MCD livers. In basal (unstimulated) conditions, little p-IR was detected whether in control or MCDfed livers. Insulin stimulation clearly increased the level of IR phosphorylation in CTL, but significantly less so in MCD livers (Figure 3 ). Akt protein expression was lower in MCD-fed than in control livers (Figure 4a and b) . A bolus of insulin induced a marked increase in Akt phosphorylation in the liver of control mice (6.5-fold increase in the ratio of pAkt/Akt), but in MCD-fed mice, minimal phosphorylation of Akt occurred in response to insulin stimulus (1.5-fold over basal values; Figure 4c and d). Livers of control and MCD-fed mice had similar basal levels of ERK1/2 protein (Figure 5a ), but as previously reported, 28, 32 basal phosphorylation of ERK1/2 is increased in MCD livers compared to controls (Figure 5a and b) . Insulin significantly increased p-ERK1/2 in control livers but not in MCD livers (Figure 5c and d) . Taken together, these data demonstrate that, despite systemic hypersensitivity to insulin, MCD-fed mice have hepatic resistance to (Figures 3 and 4) . In MCD-fed mice, PGZ treatment increased the basal expression of Akt protein to levels equal or higher to those observed in control-fed mice (Figure 4a and b) . In addition, PGZ dramatically increased the phosphorylation of both IR and Akt in response to insulin stimulus, restoring to normal the response that was almost abolished in MCD-fed mice ( Figures  3 and 4c and d) .
In controls, PGZ did not significantly modify the hepatic expression of ERK1/2 proteins, the basal level of pERK1/2 or the magnitude of the response to insulin stimulus. In MCD livers, PGZ treatment was associated with a significant increase in the basal level of p-ERK1/2, this level of phosphorylation was not further enhanced by insulin ( Figure 5 ). Thus, contrasting with the restoration of IR and Aktphosphorylation in response to insulin induced by PGZ treatment to MCD-fed mice, PGZ was not associated with a restoration of the activation of the ERK pathway by insulin. Alternatively, as PGZ treatment is associated with a significant induction of p-ERK, additional stimulation through the IR cannot be further recruited. Serine phosphorylation of IRS proteins has been shown to inhibit insulin-mediated signalling. The level of expression of IRS1 ( Figure 3 ) and IRS2 (not shown) does not significantly differ among groups. Serine phosphorylation of IRS1 was barely detectable in CTL livers, appeared more readily in MCD livers and was slightly decreased upon PGZ treatment. Insulin stimulus did not induce apparent changes in the level of phosphoserine-IRS1. This suggests that inhibitory phosphorylation of IRS1 may be a mechanism, in addition to the defect in IR phosphorylation, that plays a role in intrahepatic insulin resistance in MCD livers. Studies from Czaja's group have suggested that impaired intrahepatic insulin signalling in MCD-fed mice might be the consequence of increased CYP2E1-generated oxidative stress. 34 We therefore analysed expression of CYP2E1 mRNA and found expectedly that MCD diet induced CYP2E1 mRNA, 27 and that this induction was dampened by PGZ treatment to MCD-fed mice (Table 4) .
Inhibition of phosphoenolpyruvate carboxykinase (PEPCK), a rate-limiting enzyme in gluconeogenesis, is one of the processes by which insulin controls hepatic glucose output. PEPCK mRNA was expressed at similar levels in CTL and MCD livers. PGZ treatment significantly reduced PEPCK expression in MCD but not in control mice (Figure 6 ), while it did not alter circulating insulin levels ( Table 2 ). In line with the effect of PGZ on activation of insulin signalling molecules, downregulation of PEPCK suggests increased sensitivity to insulin in PGZ-MCD livers.
Effects of PGZ on b-Oxidation and Lipid Storage
As mentioned above, PGZ treatment inhibits hepatic steatosis caused by the MCD diet ( Figure 1 and Table  1 ). Hepatic ACO codes for the rate-limiting enzyme of fatty acids b-oxidation. ACO was reduced in the livers of MCD-fed mice compared to controls compatible with the proposal that reduced combustion of fatty acids participate to steatosis induced by the MCD diet. 29, 30 PGZ treatment to MCD-fed mice did not modify the expression of ACO (Table 4) . ACC regulates b-oxidation by controlling the levels of malonyl-coA and thereby the entrance of fatty acids into the mitochondria. MCD was associated with a 50% increase in the pACC/ACC ratio ( Figure  7a ). However, because the ACC content was decreased in those livers (Figure 7b ), the total amount of pACC was similar to that found in the liver of control mice, and unaltered by PGZ treatment (Figure 7c ). Also, hepatic mRNA expression of PPARg1-and PPARg-regulated fatty acid transporter CD36 were increased in MCD livers (Table 4) . While treatment with PPARg ligand PGZ did not alter PPARg mRNA expression, it induced CD36 expression in MCD livers (Table 4) . Therefore, although MCD diet might favour steatosis by decreasing boxidation (as suggested by decreased ACO) and increased fatty acid uptake (resulting from increased CD36 expression), reduction of steatosis observed under PGZ treatment might not be explained by a stimulation of b-oxidation, or a limitation of fatty acid transport into the hepatocytes.
Discussion
In humans, NASH occurs in association with insulin resistance and obesity. While it is accepted that hepatic fat accumulation and insulin resistance are linked, the mechanism for this relationship remains unclear. Mice fed a lipogenic diet deficient in methionine and choline are used as a model of steatohepatitis. Although those mice lose weight and have normal or hyper-normal systemic sensitivity to insulin, they develop intrahepatic insulin resistance. Our data demonstrate that PGZ prevents hepatic fat accumulation and steatohepatitis and also prevents intrahepatic insulin resistance in MCD-fed mice. Choline and methionine deficiency induces steatosis as a result of both decreased availability in phosphatidylcholine, which leads to membrane dysfunction and impaired excretion of VLDL, and altered regulation of genes controlling glucose and lipid metabolism such as ACO, the rate-limiting enzyme for b-oxidation. 29, 36 PGZ induces the production of adiponectin. 37 In the liver, adiponectin activates AMP kinase (AMPK) and PPARa leading to increased fatty acid combustion and decreased hepatic lipid content. 38 In our model, despite a twofold increase in serum adiponectin concentrations, phosphorylation of ACC (a substrate for AMPK) or PPAR-a-dependent expression of ACO were not significantly altered. This suggests that the antisteatotic effect of PGZ is not related to stimulation of hepatic lipid burning.
PPARg agonist PGZ promotes fatty acid storage and uptake in adipose tissue. 7, 35 Accordingly, the mass of subcutaneous abdominal adipose tissue increased in PGZ-treated animals. Therefore, diversion of fat from the liver to the adipocytes may participate to the reduction of steatosis by PGZ. 2, 5 Beside adipocytes, PPARg is also able to induce an adipogenic transformation of other cell types, and, in particular, hepatocytes. 39 Enhanced expression of PPARg and PPARg-regulated fatty acid transporter CD36 in the liver of MCD-fed mice suggests that PPARg may exert an adipogenic effect favouring steatosis. However, while PGZ further induces CD36 expression in MCD livers, this was associated with a dramatic reduction of steatosis. This implies that PPARg-mediated adipogenic transformation of hepatocytes has no physiological significance in this model, or, that this effect is overpowered by another antisteatotic action of PGZ.
Thus, increased intrahepatic lipid burning does not appear to be the process by which PGZ reduces steatosis in this model. Rather, the increased fat mass suggests that decreased steatosis may be the consequence of diversion of fat storage from the liver to the adipose tissue promoted by direct stimulation of PPARg in adipocytes.
Contrasting with the metabolic status in patients with NASH, MCD-fed mice lose weight, are depleted from peripheral fat, have low fasting glucose and insulin serum levels, as well as normal leptin and adiponectin levels. In accordance with others, our metabolic studies demonstrate that their tolerance to glucose and their systemic insulin sensitivity are increased, 33 an observation that has also been made in calorically restricted animals. 40, 41 Despite this, and by contrast to calorie restriction, MCD-fed mice developed significant intrahepatic insulin resistance. The activation, by insulin, of both the mitogenic (ERK) and the metabolic (Akt) pathways controlling gluconeogenesis, glycogenolysis, glycogen synthesis 42 are blunted in MCD-fed livers. Defective phosphorylation of the insulin receptor appears as an important mechanism for insulin resistance in this model, although additional blockade along the pathway may also result from increased serine (inhibitory) phosphorylation of IRS1. Treatment of MCD-fed mice with PGZ improved intrahepatic insulin resistance as demonstrated by the restoration of normal phosphorylation of IR and Akt in response to insulin stimulus, together with apparent decrease in Pserine-IRS1. Studies have documented that inappropriate regulation of glucose production by the liver is an important component of the diabetic states, and that TZD drugs exert their insulin-sensitising effect by potentiation of insulin-mediated activation of Akt. 43 In MCD-fed mice, impaired intrahepatic insulin resistance and defective activation of Akt were not associated with altered expression of PEPCK, a rate-limiting enzyme in gluconeogenesis nor with decreased glucose-lowering effect of insulin in vivo. TZD treatment had remarkable effect on intrahepatic insulin signalling and downregulation of PEPCK. In turn, this could explain, via better control of insulin over hepatic glucose output, the faster decrease of blood glucose levels after glucose challenge in TZD-treated MCD mice. However, and contrasting with this proposition, the treatment had no significant consequence on in vivo response to insulin. As systemic insulin sensitivity is clearly enhanced, increased glucose uptake by peripheral tissue may compensate for increased hepatic glucose output expected from intrahepatic insulin resistance in MCD-fed mice. Alternatively, hepatic glucose production might be limited in these animals as a consequence of cachexia and depleted hepatic glycogen stores. Hyperinsulinemic clamp studies and analysis of muscle and adipose insulin signalling are needed for further understanding.
Whether, under PGZ treatment, amelioration of intrahepatic insulin resistance is the cause or the consequence of improved peripheral insulin sensitivity has been debated. 4, 6, 8 In our setting, systemic and intrahepatic insulin resistances are clearly dissociated and correction of intrahepatic insulin resistance by PGZ is independent on systemic insulin sensitisation. Adiponectin-dependent control of hepatic glucose production appears as a critical mediator of PPARg-agonist-mediated improvement of insulin sensitivity. 6, 44, 45 The two-fold increase in serum adiponectin concentrations induced by PGZ treatment was associated with decreased expression of PEPCK and restoration of intrahepatic insulin sensitivity in MCD-fed livers; while a similar increase in adiponectin in control mice does not significantly affect insulin-dependent signalling cascade. On the other hand, accumulation of intracellular fatty-acid metabolites and hepatic steatosis may lead to hepatic insulin resistance, by direct interference with intermediate effectors of intracellular IR-dependent signalling pathways. 24, 26 Such alteration may also be produced by reactive oxygen species generated by CYP2E1, whose expression is induced in the liver of MCD-fed mice. 27, 34 PGZ treatment to MCD-fed mice resulted in the clearance of steatosis, decreased induction of CYP2E1 and improvement of intrahepatic insulin signalling. Increase in lipid metabolites (which are substrates for CYP2E1) has been proposed as a plausible mechanism for CYP2E1 induction in MCD livers. 27, 29 To the best of our knowledge, the participation of PPARg in CYP2E1 gene regulation has never been explored. Because PGZ does not influence the level of CYP2E1 expression in normal livers, prevention of CYP2E1 upregulation by PGZ in MCD livers is more likely linked to decreased fat. Therefore, abolition of CYP2E1 induction might mechanistically participate to the restoration of intrahepatic insulin sensitivity associated with steatosis clearance induced by PPARg agonists in this model. Experiments using adiponectin KO mice might be helpful in determining the respective roles of adiponectin and decreased steatosis by preferential storage of fat in the adipose tissue in the hepatic insulin-sensitising effect of PGZ in MCD-induced steatohepatitis.
Finally, PGZ reduced hepatic inflammation and early fibrogenesis in MCD-fed mice. As demonstrated elsewhere, clearance of hepatic lipids is sufficient to prevent or revert steatohepatitis. 29, 30 Additionally, modulation of inflammation by PPARg itself or PPARg-regulated adipocytokines might be implicated. [46] [47] [48] [49] Additional studies using mice null for adipocytokines or their receptors or in which PPARg will be conditionally and tissue specifically knocked-down would be required to delineate the specific roles of adipose tissue, liver and inflammatory cells in decreased inflammation obtained by PPARg agonist treatment. PGZ, as described in several other studies, 50 increases the activation of the MAPK/ERK pathway, and particularly so in MCD livers. Because MAPKs are well-known growth regulators, it will be interesting to test in further studies whether PGZ-induced activation of this pathway stimulates the replacement of damaged hepatocytes and thereby decreases noxious consequences of steatohepatitis.
In conclusion, in the MCD diet model of steatohepatitis, there is dissociation between enhanced systemic insulin sensitivity and intrahepatic resistance to insulin. PGZ treatment to MCD-fed mice alleviates steatosis and steatohepatitis. This effect was associated with improved intrahepatic insulin sensitivity. Our data support the proposition that reduced steatosis under PGZ treatment is at least partly the consequence of diversion of fat from liver to adipose storage. Reduced steatosis, prevention of CYP2E1 induction and increased serum adiponectin might mechanistically participate to the restoration of intrahepatic insulin sensitivity in PGZ-treated MCD-fed mice.
